These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 14509872)

  • 1. Determinants of health-related quality of life in HIV-infected patients.
    Murri R; Fantoni M; Del Borgo C; Visona R; Barracco A; Zambelli A; Testa L; Orchi N; Tozzi V; Bosco O; Wu AW
    AIDS Care; 2003 Aug; 15(4):581-90. PubMed ID: 14509872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life and survival among HIV-infected patients receiving highly active antiretroviral therapy: a study of patients in the AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort.
    de Boer-van der Kolk IM; Sprangers MA; Prins JM; Smit C; de Wolf F; Nieuwkerk PT
    Clin Infect Dis; 2010 Jan; 50(2):255-63. PubMed ID: 20014949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends and predictors of quality of life among HIV-infected adults taking highly active antiretroviral therapy in rural Uganda.
    Stangl AL; Wamai N; Mermin J; Awor AC; Bunnell RE
    AIDS Care; 2007 May; 19(5):626-36. PubMed ID: 17505923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
    Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and impact of diarrhea on health-related quality of life in HIV-infected patients in the era of highly active antiretroviral therapy.
    Siddiqui U; Bini EJ; Chandarana K; Leong J; Ramsetty S; Schiliro D; Poles M
    J Clin Gastroenterol; 2007; 41(5):484-90. PubMed ID: 17450031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of cytomegalovirus retinitis on the quality of life of patients with AIDS in the era of highly active antiretroviral therapy.
    Kempen JH; Martin BK; Wu AW; Barron B; Thorne JE; Jabs DA;
    Ophthalmology; 2003 May; 110(5):987-95. PubMed ID: 12750102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life and social support among patients receiving antiretroviral therapy in Western Uganda.
    Bajunirwe F; Tisch DJ; King CH; Arts EJ; Debanne SM; Sethi AK
    AIDS Care; 2009 Mar; 21(3):271-9. PubMed ID: 19280404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART.
    Tozzi V; Balestra P; Murri R; Galgani S; Bellagamba R; Narciso P; Antinori A; Giulianelli M; Tosi G; Fantoni M; Sampaolesi A; Noto P; Ippolito G; Wu AW
    Int J STD AIDS; 2004 Apr; 15(4):254-9. PubMed ID: 15075020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life and associated factors in people with HIV: an Irish cohort study.
    George S; Bergin C; Clarke S; Courtney G; Codd MB
    Health Qual Life Outcomes; 2016 Aug; 14(1):115. PubMed ID: 27495166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3.
    Revicki DA; Swartz C; Wu AW; Haubrich R; Collier AC
    Antivir Ther; 1999; 4(1):35-44. PubMed ID: 10682127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs.
    Le Moing V; Thiébaut R; Chêne G; Sobel A; Massip P; Collin F; Meyohas M; Al Kaïed F; Leport C; Raffi F;
    HIV Med; 2007 Apr; 8(3):156-63. PubMed ID: 17461859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life and patient-provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment.
    Préau M; Leport C; Salmon-Ceron D; Carrieri P; Portier H; Chene G; Spire B; Choutet P; Raffi F; Morin M
    AIDS Care; 2004 Jul; 16(5):649-61. PubMed ID: 15223534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evidence-based medicine and the validation of quality-of-life questionnaires: the Spanish version of the MOS-HIV questionnaire for the evaluation of the quality of life in patients infected by HIV].
    Badía X; Podzamczer D; López-Lavid C; García M
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():103-13. PubMed ID: 10605195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
    Omland LH; Weis N; Skinhøj P; Laursen A; Christensen PB; Nielsen HI; Møller A; Engsig F; Sørensen HT; Obel N
    HIV Med; 2008 May; 9(5):300-6. PubMed ID: 18400077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
    Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.